Steven A. Middleton
La Roche College(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Receptor Mechanisms and Signaling, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Urinary Bladder and Prostate Research
Most-Cited Works
- → Crystallographic Evidence for Preformed Dimers of Erythropoietin Receptor Before Ligand Activation(1999)596 cited
- → Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å(1996)592 cited
- → Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study(2012)555 cited
- → Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors(2012)278 cited
- → Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors(2009)127 cited
- → 1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors: Synthesis and Evaluation of Biological Activities(2005)127 cited
- → The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases(2005)124 cited
- → Synthesis of 3-(1H-benzimidazol-2-yl)-5-isoquinolin-4-ylpyrazolo[1,2-b]pyridine, a potent cyclin dependent kinase 1 (CDK1) inhibitor(2006)108 cited
- → Identification of a 13 Amino Acid Peptide Mimetic of Erythropoietin and Description of Amino Acids Critical for the Mimetic Activity of EMP1(1998)101 cited
- → Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors(2005)92 cited